Explore All 2731 Add-on Acquisition Medical Products Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | July 1, 2014 |
| Target | ECP Entwicklungsgesellschaft mbH |
| Sector | Medical Products |
| Buyer(s) | Abiomed |
| Deal Type | Add-on Acquisition |
| Deal Value | 13M USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1981 |
| Sector | Medical Products |
| Employees | 1,725 |
| Revenue | 1.0B USD (2022) |
Abiomed is a cardiovascular device company. Abiomed develops, manufactures, and markets medical products designed to establish recovery's as the standard of care for acute patients. Abiomed was formed in 1981 and is based in Danvers, Massachusetts.
| Deal Context for Buyer | # |
|---|---|
| Overall | 2 of 4 |
| Sector: Medical Products | 2 of 4 |
| Type: Add-on Acquisition | 2 of 4 |
| Country: Germany | 2 of 2 |
| Year: 2014 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-04-27 |
Impella CardioSystems AG
Aachen, Germany Impella CardioSystems AG, develops, manufactures and markets minimally invasive cardiovascular support systems for numerous indications in the fields of cardiology and coronary surgery. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-04-29 |
Breethe
Longueuil, Quebec, Canada Breethe, Inc. is a developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock or respiratory failures such as due to ARDS, H1N1, SARS, or COVID-19. ECMO has also been utilized as a primary method of oxygenation and hemodynamic support for pediatric patients. Breethe was founded in 2014 and is based in Longueuil, Quebec. |
Buy | - |
